The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
A vaccine to interrupt the transmission of tuberculosis is needed. ⋯ M72/AS01E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598 .).